The Department for International Trade (DIT) invites innovative British biopharmaceutical companies across:
- Drug discovery/re-purposing and delivery
- Process Manufacturing including AI/data in manufacturing
Vaccines: India is a global vaccines hub as the country produces more than 60% of vaccine doses procured by the UN worldwide. India also has the largest global capacity for WHO pre-qualified vaccine manufacturing.
Several Indian vaccine manufacturers are developing vaccines for infectious and non- infectious diseases, including for Covid-19 either indigenously and/or in partnership with international organisations.
Drug discovery and delivery: India is the largest provider of generic drugs globally, supplying over 40 per cent of generic demand in the US, and 25 per cent of all medicine in UK, through more than 250 US FDA, and UK MHRA approved plants. Indian manufacturers are moving up the value chain by investing in R&D for development of new molecules. There is also renewed interest in drug re-purposing, to identify new areas of application for existing drugs, especially with the current pandemic situation.
Process manufacturing and technology: as Indian pharma moves up the value chain, there are increased incentives to investing in technologies such as those included within Industry 4.0 and digital manufacturing to improve processes and costs, which would enable India to meet the high regulatory standards of markets like the US and EU. Given the UK’s strengths in above areas, the UK stands out as the perfect partner of choice for the Indian biopharma industry as it looks to move up the value chain.